[Inhibitor-protected aminopenicillins. Pharmacological characterization and role in community-acquired infections].
Guchev
I A
IA
Melekhina
E V
EV
D019980:Amoxicillin-Potassium Clavulanate Combination / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000667:Ampicillin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000668:Ampicillin Resistance; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010349:Patient Compliance; D065093:beta-Lactamase Inhibitors
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D065093:beta-Lactamase Inhibitors; D019980:Amoxicillin-Potassium Clavulanate Combination; D000667:Ampicillin